FDA
-
-
-
-
-
-
-
Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine
-
-
-
-
-
-
-
Pre-Open Movers 12/10: (VERI) (NTRI) (MGNX) Higher; (AXON) (NAV) (AAPL) Lower (more...)
-
-
-
-
-
-
-
Achaogen Highlights Multiple Plazomicin Presentations at IDWeek 2018
-
-
-
-
-
-
-
CMS Grants New Technology Add-on Payment to ZEMDRI™ (plazomicin)
-
-
-
-
-
-
-
Achaogen to Host Investor Lunch Updating Investors on Commercial Strategy Post FDA Approval of Plazomicin on July 12th in New York City
-
-
-
-
-
-
-
ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
-
-
-
-
-
-
-
Achaogen (AKAO) Provides Summary of FDA Advisory Committee Votes on Plazomicin
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

